Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Elicitation of health state utilities in neuroendocrine tumours.
Swinburn P, Wang J, Chandiwana D, Mansoor W, Lloyd A. Swinburn P, et al. Among authors: chandiwana d. J Med Econ. 2012;15(4):681-7. doi: 10.3111/13696998.2012.670175. Epub 2012 Mar 20. J Med Econ. 2012. PMID: 22364284 Free article.
Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2- advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2.
Cameron D, Kumar Sharma V, Biswas C, Clarke C, Chandiwana D, Pathak P. Cameron D, et al. Among authors: chandiwana d. J Med Econ. 2023 Jan-Dec;26(1):357-365. doi: 10.1080/13696998.2023.2182051. J Med Econ. 2023. PMID: 36797664 Free article.
Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective.
Stellato D, Thabane ME, Park J, Chandiwana D, Delea TE. Stellato D, et al. Among authors: chandiwana d. Pharmacoeconomics. 2021 Sep;39(9):1045-1058. doi: 10.1007/s40273-021-01027-4. Epub 2021 Jun 9. Pharmacoeconomics. 2021. PMID: 34105083
Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2- Advanced Breast Cancer.
Fasching PA, Delea TE, Lu YS, De Boer R, Hurvitz SA, Moynahan A, Chandiwana D, Lanoue B, Hu H, Thuerigen A, O'Shaughnessy J. Fasching PA, et al. Among authors: chandiwana d. Cancer Manag Res. 2021 Nov 1;13:8179-8189. doi: 10.2147/CMAR.S325043. eCollection 2021. Cancer Manag Res. 2021. PMID: 34754238 Free PMC article.
Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2- Advanced Breast Cancer in the MONALEESA-3 Trial.
Jerusalem G, Delea TE, Martin M, De Laurentiis M, Nusch A, Beck JT, Chan A, Im SA, Neven P, Lonshteyn A, Chandiwana D, Lanoue B, Fasching PA. Jerusalem G, et al. Among authors: chandiwana d. Clin Breast Cancer. 2022 Jun;22(4):326-335. doi: 10.1016/j.clbc.2021.12.008. Epub 2021 Dec 20. Clin Breast Cancer. 2022. PMID: 35034858 Clinical Trial.
29 results